Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9766420 | 0.98 | GNAI3 (0.55) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL8805965 | 0.98 | GNAI3 (0.55) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL28783280 | 0.98 | GNAI3 (0.55) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL4629578 | 0.98 | GNAI3 (0.55) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL2103662 | 0.93 | GNAI3 (0.43) | GNAI3GNAO1GNAI1ALDH1A1CYP1A2 | |
| SCHEMBL7538960 | 0.92 | GNAI3 (0.46) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL1081412 | 0.86 | GNAO1 (0.44) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL16799683 | 0.85 | GNAO1 (0.47) | GNAI3GNAO1GNAI1KDM4EGAA | |
| SCHEMBL727664 | 0.82 | — | — | |
| SCHEMBL1043043 | 0.82 | GNAI3 (0.70) | GNAI3GNAO1GNAI1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077387-B1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | claimed |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-07-06 | — | — | US | claimed |
| US-9562035-B2 | Benzamide derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | claimed |
| EP-3077387-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2016-10-12 | — | — | EP | claimed |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | claimed |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-20 | — | — | US | claimed |
| EP-2906221-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | Southern Research Institute (US) | 2015-08-19 | — | — | EP | claimed |
| WO-2015084606-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | WO | claimed |
| CN-102153544-B | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | claimed |
| WO-2014059265-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2014-04-17 | — | — | WO | claimed |
| JP-4613157-B2 | — | — | 2011-01-12 | — | — | JP | claimed |
| EP-1615878-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2007-09-19 | — | — | EP | claimed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | claimed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | claimed |
| JP-2006515884-A | — | — | 2006-06-08 | — | — | JP | claimed |
| EP-1615878-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2006-01-18 | — | — | EP | claimed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | claimed |
| WO-2004064730-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| EP-1129073-A2 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF DONEPEZIL AND RELATED COMPOUNDS | Finetech Ltd (IL) | 2001-09-05 | — | — | EP | claimed |
| WO-2000009483-A2 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF DONEPEZIL AND RELATED COMPOUNDS | FINETECH LTD. (IL) | 2000-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | HTR2C, HTR4, HTR2A | GNAI3 2216/4885GNAO1 1702/4885GNAI1 2909/4885 |
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | GNAI3 1971/4885GNAO1 2092/4885GNAI1 2000/4885 |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | DRD2, CHRM2, NPY2R | GNAI3 1515/4885GNAO1 2104/4885GNAI1 2011/4885 |
| US-20070066626-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | GNAI3 1819/4885GNAO1 2013/4885GNAI1 1898/4885 |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, FABP1, BCL3 | GNAI3 2940/4885GNAO1 3267/4885GNAI1 2771/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | GNAI3 1819/4885GNAO1 2013/4885GNAI1 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.